

Please try another search
For the fiscal year ended 31 December 2021, Vifor Pharma AG revenues increased 3% to SF1.75B. Net income before extraordinary items increased 6% to SF146.6M. Revenues reflect Europe (Region)-Switzerland (Country) segment increase of 14% to SF494.2M. Net income benefited from Securities and other financial income increase from SF15.1M to SF49.5M (income), Net foreign exchange differences decrease of 71% to SF9.1M (expense).
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 894.9 | 859.3 | 783.1 | 846.2 |
Gross Profit | 552.8 | 529.6 | 457.8 | 500.3 |
Operating Income | 104.7 | 177.4 | 156.4 | 113.5 |
Net Income | 19.9 | 124.5 | 291.7 | 67.9 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 5099.6 | 4916.3 | 5211.7 | 4899.5 |
Total Liabilities | 1609.7 | 1545.1 | 1641.9 | 1606.2 |
Total Equity | 3489.9 | 3371.2 | 3569.8 | 3293.3 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 12 Months | 6 Months |
Cash From Operating Activities | 527.3 | 189.7 | 423.8 | 172.5 |
Cash From Investing Activities | -48.8 | -98.6 | 52.4 | -152.8 |
Cash From Financing Activities | -210.9 | -208.9 | -268.4 | -254 |
Net Change in Cash | 263.5 | -103.9 | 185.1 | -240.2 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review